Jubilant Therapeutics reports preclinical information of double LSD1 and HDAC6 at AACR 2020 Kumar Jeetendra | June 23, 2020 Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The preclinical …
Newfound substance compound demonstrates potential to become treatment for mind issues Kumar Jeetendra | July 13, 2020 Researchers at IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) discovered a novel compound compound, that has got the capacity to became a new medication for the treatment of heart symptoms of brain ailments such as Down syndrome and pneumonia. These results are available in preclinical models where the new chemical ameliorated difficulties in cognitive …
Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals Kumar Jeetendra | July 25, 2020 Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. MRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune …
Novel medication could improve future and quality for patients with difficult to-treat malignant growths Kumar Jeetendra | September 9, 2020 The Sheffield researchers founded the spin-out Modulus Oncology with a group of experienced biotech entrepreneurs to fast-track the drug into clinical testing over two decades. The researchers founded the spin-out firm Modulus Oncology, along with a team of seasoned biotech entrepreneurs, to fast-track the drug into clinical testing over two years. The Sheffield team made …
Drug used to control pulse may improve malignant growth patients’ reaction to immunotherapy Kumar Jeetendra | November 1, 2020 The exact same biochemical triggers which spur a”flight or fight” reaction once we encounter threats may help tumor cells to thrive. A group of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to interrupt that dynamic so that cancer therapies can be effective. Their latest work, published today in Clinical Cancer Research, …
Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
Conceivable new anti-microbial created for drug-resistant pulmonary microorganism Kumar Jeetendra | December 9, 2020 Scientists from Johns Hopkins University and Medicine have developed a potential new antibiotic for a pathogen that is notoriously resistant to drugs and often lethal for people with cystic fibrosis and other lung disorders. The pathogen, called Mycobacterium abscessus, is related to some better-known bacterium that causes tuberculosis and leprosy but has recently emerged as …
Pig stem cells offer another approach to develop human organs for transplantation Kumar Jeetendra | December 18, 2020 In a new paper published in Stem Cell Reports, Bhanu Telugu and co-inventor Chi-Hun Park of the University of Maryland (UMD) Department of Animal and Avian Sciences show for the first time that newly generated stem cells from cows, when injected into embryos, contributed to the growth of only the organ of interest (the embryonic …
new cGMP plasmid DNA manufacturing facility construction announced by Thermo Fisher Kumar Jeetendra | December 18, 2020 Thermo Fisher Scientific, the world leader in serving science, today announced the construction of a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif. The site will expand the company’s clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer …
New gene based vaccine procedure gets award from the Bill and Melinda Gates Foundation Kumar Jeetendra | January 29, 2021 The AAVCOVID vaccine application, a novel gene-based vaccine plan that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. The grant will assist the effort to bring further preclinical validation into the AAV vaccine platform. An AAVCOVID vaccine candidate is set to …
Hydrogel injection could help fix harm to the heart muscle after heart attack Kumar Jeetendra | February 19, 2021 Researchers at CÚRAM, the SFI Research Centre for Medical Devices based at NUI Galway, and BIOFORGE Lab, at the University of Valladolid in Spain, have developed an injectable hydrogel which might help repair and prevent additional damage to the heart muscle following a heart attack occasion. The results of their research have only been published …
Drug-discovery collaboration discovers potential new antimalarial drug candidates Kumar Jeetendra | April 23, 2021 Potential new antimalarial drug candidates are being developed through an protracted drug-discovery collaboration between Australian medical research institute WEHI and Janssen Pharmaceutica NV. The collaboration was facilitated by Johnson & Johnson Innovation. A collaborative research team discovered compounds with antimalarial activity within a collection of 80,000 drug-like molecules at the Janssen Jump-stARter Compound Library, a …
